GAA AGM Results from 29/11/2006
At the Genepharm AGM held on 29 Nov 2006 -
Chairman O’Brien said that the company expected to report nett revenue for Q4 2006 of about $2.2mill.
MD Dennis Bastas reported -
New drug registrations -
Pravastatin - August 06
Zolpiderm (sleep disorder) - October 06
Paroxetine (anti-depressant) - expected December 06
Sales comparison July 05 to July 06 – sales up about 30%.
The figures -
1. GAA is now turning a profit - for the period 1 July to 30 Sept 06
Gross sales $21 mill.
Nett sales $12.4 mill.
Gross Profit $5.2 mill.
Cash at bank $10.2 mill.
Debt: NIL.
Forecast for the full 06/07 financial year was
Gross sales - $110 mill to $120 mill.
Nett sales - $60 mill to $65 mill.
One shareholder asked when the company expected to pay a dividend and CFO Harding said he looked forward to commencing dividends in 07/08 provided of course the company continues to show a profit.
The MD in closing the meeting was upbeat about the company’s prospects.
- Forums
- ASX - By Stock
- GAA
- genepharm agm results
GAA
genepharm australasia limited
genepharm agm results
Featured News
Add GAA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online